SEC Form 4 · accession 0001140361-15-044876
CYTRX CORP · CYTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Scott Wieland
Officer — Sr VP - Drug Development
Period of report
Dec 15, 2015
Accepted (ET)
Dec 17, 2015 · 1:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000799698
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.44 | Dec 15, 2015 | A | 100,000 | A | — | Dec 14, 2025 | CytRx Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The Stock Option vests monthly for 36 months in equal installments, beginning 15 January 2016, provided Reporting Person remains in continuous employ of issuer.